Compare Ambarella Inc (AMBA) vs Cassava Sciences Inc (FLNA) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.